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Abstract 1 
Catheter ablation of atrial fibrillation (AFCA) is a widely recommended treatment for symptomatic 2 
AF patients refractory to pharmacological treatment. AFCA is becoming a therapeutic option also 3 
among patients with heart failure (CHF), on top of optimal medical treatment, being this arrhythmia 4 
related to a higher risk of death and/or symptom’s worsening. In fact, in this setting, clinical 5 
evidences are continuously increasing.  6 
The present systematic review pools all published experiences concerning AFCA among CHF 7 
patients, or patients with structural cardiomyopathies, in order to summarize procedural safety and 8 
efficacy in this specific population. Moreover, the effects of AFCA on functional class and quality 9 
of life and the different procedural protocols available are discussed.  10 
The present work, therefore, attempts to provide an evidence based clinical perspective to optimize 11 
clinical indication and tailor procedural characteristics and endpoints to patients affected by CHF 12 
referred for AFCA. 13 
14 
4 
 
Introduction 1 
Atrial fibrillation (AF) and chronic heart failure (CHF) are two strictly related epidemics of modern 2 
cardiovascular medicine
1
, as demonstrated by their increasing prevalence in the general population
2
. 3 
They share pathophysiological links, as CHF is related to AF occurrence through the increase of left 4 
ventricular (LV) filling pressures, left atrial dilation and fibrosis, that all lead to atrial structural and 5 
electrical remodeling
3,4
. On the other side AF increases the risk of developing CHF through the loss 6 
of atrial contraction, short and irregular cardiac cycles and uncontrolled heart rate secondary to the 7 
arrhythmia. This may ultimately lead to impaired ventricular filling, contractility and reduced 8 
cardiac output
5,6
.  9 
As AF can increase mortality in this population
7
, the treatment of AF in patients with CHF plays a 10 
relevant role. In fact, rhythm control has recently proven beneficial in large observational cohorts, 11 
reporting longer survival
8
, decreased incidence of stroke
9
 and silent cerebral ischemic lesions
10
, 12 
compared to rate control strategies. However, the optimal rhythm control option is still of concern, 13 
as the majority of antiarrhythmic drugs carry a high risk of adverse effects, such as pro-14 
arrhythmias
11
, negative inotropic effect potentially worsening heart failure status
12
, and only 15 
amiodarone is permitted, but presents frequent extra-cardiac adverse effects
13,14
. Dronedarone, 16 
following the results of the Antiarrhythmic trial with DROnedarone in Moderate-to-severe 17 
congestive heart failure Evaluating morbidity DecreAse (ANDROMEDA)
15
, is not recommended 18 
for patients with moderate to severe HF and should be avoided in patients with less-severe HF if 19 
appropriate alternatives exist
14
. 20 
Catheter ablation of AF (AFCA) is an established therapeutic option in patients symptomatic from 21 
AF despite adequate rate control and pharmacologic rhythm control
14
. Within the general 22 
population, to date, the safety and efficacy rates promoted this procedure to the first choice 23 
following one antiarrhythmic drug failure and, in selected patients, even the first option before 24 
drugs
14
. 25 
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Its role within CHF patients, instead, is less well defined. Small randomized trials and observational 1 
studies, and recently a meta-analysis including up to 1,800 patients, have assessed the role of AFCA 2 
in CHF patients. The present systematic review aims to discuss patients’ selection, safety, efficacy 3 
and clinical implications of AFCA in the setting of CHF. 4 
 5 
Methods 6 
The present study was conducted in accordance to current guidelines, including the recent Preferred 7 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality 8 
of Reporting of Meta-analyses (QUOROM) statement
16
. 9 
A systematic review was conducted to retrieve all published data concerning AFCA in patients with 10 
CHF. MEDLINE/PubMed and Cochrane database were searched for pertinent articles published in 11 
English from 2002 until January 2015, according to published recommendations
17
. The following 12 
terms: “atrial fibrillation” AND “catheter ablation” AND “heart failure” AND (“clinical trial” OR 13 
“meta-analysis” OR “observational study”) were used to identify all the published articles referring 14 
to this specific patient population. Moreover, a second search was performed to identify published 15 
data concerning AFCA in patients with specific structural cardiomyopathies. The following terms: 16 
“atrial fibrillation” AND “catheter ablation” AND (“cardiomyopathy” OR “valvular”) AND 17 
(“clinical trial” OR “meta-analysis” OR “observational study”) were used. 18 
Retrieved citations were first screened independently by 2 reviewers (authors: M.A. and M.M.). If 19 
the citations were deemed potentially pertinent, they were then appraised as complete reports 20 
according to the following selection criteria: (i) human studies, (ii) published between 2002 and 21 
December 2014, (iii) investigating patients with impaired LV systolic function, defined as LVEF < 22 
50%, or with specific cardiomyopathies, undergoing AFCA. Exclusion criteria were: (i) non-human 23 
6 
 
setting, (ii) duplicate reporting (in which case the manuscript reporting the largest sample of 1 
patients was selected), (iii) studies including patients undergoing surgical or hybrid AF ablation, or 2 
(iv) studies without comprehensive follow-up description. 3 
 4 
Search Results 5 
The first search identified 169 abstracts; among this group, 144 were excluded following 6 
application of the inclusion and exclusion criteria; 25 of them were finally selected and included, in 7 
particular 17 observational studies
18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34
 4 randomized controlled trials 8 
(RCTs)
35,36,37,38
 and 4 meta-analyses
39,40,41,42
. Details concerning sample size and main findings for 9 
each of the studies considered are summarized in Table 1 and Table 2. The second search identified 10 
50 abstracts; among this group, 36 were excluded following application of the inclusion and 11 
exclusion criteria; 14 of them were finally selected, in particular one study including patients with 12 
tachycardiomyopathy (TCM)
43
, 8 studies including patients with hypertrophic cardiomyopathy 13 
(HCM)
44,45,46,47,48,49,50,51
,  and 5 studies including patients with valvular cardiomyopathy
52,53,54,55,56
. 14 
 15 
Observational studies 16 
As detailed in Table 1 observational studies included 1,253 patients. Follow-up ranged from 6 to 60 17 
months. Mean efficacy of AFCA in maintaining sinus rhythm (SR) was 48% after the first 18 
procedure, raising up to 75% including the 32% of the patients undergoing a redo procedure. All the 19 
included patients underwent pulmonary veins (PV) isolation, and 55% received additional left atrial 20 
lesions: left isthmus line, roof line and complex fractioned atrial electrograms (CFAE) ablation. 21 
Complications rate was 4.3%. Several studies reported on improvement of  LV systolic 22 
7 
 
function
19,20,21,24,25,26,27,28,29,30
, quality of life, exercise tolerance
18,19,20,27
, mitral regurgitation
28
 and 1 
reduction of heart failure hospitalizations
33
.  2 
 3 
Randomized controlled trials 4 
The four available RCTs included 115 patients overall (Table 1). The control groups included 5 
patients undergoing atrioventricular node ablation and biventricular pacemaker implantation in the 6 
trial by Khan et al.
35
, while patients treated with optimal medical therapy and rate control 7 
management in the other three trials. Follow-up ranged from 6 to 10 months. Mean efficacy of 8 
AFCA in maintaining SR was 59% after the first procedure, raising up to 77% including the 31% 9 
patients undergoing redo procedures. All patients included underwent PV isolation, and 98% 10 
received additional left atrial lesions. Complications rate was 12%. Three of four studies found 11 
quality of life and functional improvement, respectively measured by 6-minute walking test 12 
(6MWT)
35
 and peak VO2 at cardiopulmonary exercise test
37,38
. 13 
 14 
AFCA in patients with TCM 15 
Two studies (Table 1) selectively focused on patients with TCM, including 113 patients 16 
respectively with a follow-up of 6 and 18 months. AFCA efficacy at follow-up was 74%, and mean 17 
LV ejection fraction (LVEF) significantly improved form 35-40% to 54%. Of note, in both studies 18 
the presence of TCM was not related to increased risk of AF recurrences
29,43
. 19 
 20 
AFCA in specific cardiomyopathies and valvular heart disease 21 
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As listed in Table 2, 8 studies described the outcome of AFCA in HCM, including 242 patients with 1 
a follow-up ranging from 6 to 30 months. Mean efficacy after a first ablation procedure was 46%, 2 
improving to 71% including over 30% of the patients with a redo procedure. Of note, the majority 3 
of these studies, especially those reporting long-term follow-up, approached AF by extensive left 4 
atrial ablation including PV isolation, linear lesions and CFAE ablation.  5 
Five studies reported the outcome of AFCA in patients with significant valvular cardiomyopathy, 6 
defined as at least moderate mitral or aortic regurgitation or stenosis or previous valvular surgery, 7 
including 259 patients followed for 11 to 54 months. Mean efficacy after a first ablation procedure 8 
was 49%, improving to 77% including the over 40% of patients undergoing redo procedures. 9 
 10 
 11 
Discussion 12 
AFCA in CHF patients: past evidence and new perspectives 13 
The majority of available data are based on small observational single center studies, mainly 14 
retrospective. Overall the procedure envisaged PV isolation for all the patients. A large proportion 15 
of patients, according to the current knowledge of AF pathophysiology and the available tools
57
, 16 
underwent additional linear lesions (e.g. the “7 scheme”58, a lesion set including, besides PV 17 
isolation, a roof line connecting ipsilateral superior PVs and a mitral isthmus line connecting left 18 
inferior PV to the mitral annulus, or CFAE ablation
59
). The first studies reported encouraging 19 
results, showing favorable trends in AFCA efficacy (ranging from 70 to 80%). However, these 20 
results referred to a short (6-12 months) follow-up. Moreover, a relatively large number of repeated 21 
procedures (in around one third of the patients) was described. In general, the complex 22 
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electroanatomical substrate of these patients
4
 seems not to impact the outcome of AFCA, although 1 
it is likely to be associated with the need of multiple procedures to maintain SR. 2 
Four studies are characterized by long-term follow-up (more than 2 years)
23,28,30,33
, showing lower 3 
efficacy rates after a single procedure (about 40-50%), raising significantly when including redo 4 
procedures. Of note, despite more procedures were performed per patient, complication rate was 5 
similar to previous studies. 6 
Several studies reported improvement of quality of life and exercise capacity
18,19,20
 following 7 
AFCA. Bunch et al.
33
 are the only reporting long-term reduction of mortality and hospitalization for 8 
heart failure following AFCA compared to medical therapy. Although carrying limitations, such as 9 
the absence of follow-up pre-specified protocols, this finding surely warrants further attention and 10 
testing in RCTs. 11 
Four short term RCTs have been performed on a limited population. These studies confirmed safety 12 
and efficacy of the procedure, except from MacDonald et al.
36
 that reported lower success rates and 13 
no improvement in LVEF or exercise tolerance. However, it should be heeded that patients included 14 
in this study had advanced CHF, longer AF duration and a worse functional class (approximately 15 
90% of the patients were in New York Heart Association functional class III) compared with the 16 
other 3 RCTs. In fact, in these trials, including patients with less severe CHF, LVEF, quality of life 17 
and exercise capacity improved significantly. Of note, complication rate was higher compared to 18 
observational studies: the reasons may be secondary to the high proportion of patients with 19 
advanced CHF compared to the other studies, often treated with extensive left atrial ablation, 20 
requiring longer procedural times and potential risk of complications. However, concerning SR 21 
restoration, there was no substantial difference between observational studies and the four RCTs. 22 
Among patients with CHF and underlying cardiomyopathy the procedure, may carry higher risks, 23 
10 
 
but, unless the patients are affected by advanced CHF and present with poor functional class, can 1 
result effective.  2 
As summarized in Table 3 four meta-analyses have been published including the aforementioned 3 
studies. In the first two works, including maximum 800 patients
39,40
, the Authors concluded that 4 
single AFCA in CHF patients is less effective than in patients without structural disease, but 5 
improves including redo procedures, without higher risks of complications; both analysis reported 6 
significant improvement in LVEF over follow-up. The third multi-center, collaborative meta-7 
analysis, including more than 1,800 patients
41
, reported, over a mean follow-up of 2 years, a similar 8 
improvement in LVEF, and particularly focused on the reduction in the proportion of patients with 9 
severely depressed LV function. This finding, previously reported by a single center study
60
, is of 10 
paramount clinical importance since potentially confers to AFCA, on top of optimal medical 11 
treatment, the ability to reduce the proportion of patients further requiring implantation of 12 
cardioverter defibrillators. Of note, AFCA efficacy and safety were similar to the data reported in 13 
the long-term follow-up of general population studies
61,62
. Time to first AF diagnosis and heart 14 
failure diagnosis significantly related to AFCA outcome, highlighting the importance of prompt 15 
optimal treatment of both CHF and AF to achieve the best clinical benefit.  16 
Eventually, within the general CHF population undergoing AFCA one small observational 17 
prospective study specifically investigated patients with preserved LVEF
34
. This study, including 74 18 
patients with mean follow-up of 34 months, reported 27% efficacy after the first procedure, raised 19 
to 73% including redo procedures and antiarrhythmic drugs. All the patients underwent PV 20 
isolation, 59% linear ablation and 27% CFAE ablation, without major complications. Of note, LV 21 
diastolic function and systolic function measured with strain and strain rate improved only in 22 
patients maintaining stable SR. These finding are in accordance with a previous study by Tops et al. 23 
11 
 
showing a significant improvement of LV circumferential and longitudinal strain and strain rate 1 
after successful AFCA, which in contrast decrease in patients experiencing AF recurrence
63
. 2 
 3 
AFCA in patients with TCM 4 
Two studies specifically focused on patients with TCM
29,43
, and both agreed that TCM itself is not 5 
related to higher AF recurrence following AFCA. The same finding was reported in a long-term 6 
follow up sub-analysis by Anselmino et al.
28
, highlighting the benefits of AFCA in this subset. 7 
Being the procedure performed after the failure of pharmacological rhythm or rate control 8 
strategies, effective SR restoration and consequent avoidance of uncontrolled high ventricular rates 9 
is pivotal in restoring normal LV function
64
. This subset of patients is, in fact, the most likely to 10 
recover normal LVEF following successful AFCA, and ablation, in this setting, proved to be 11 
superior to effective rate control in normalizing LV function
43
. In addition, being TCM a significant 12 
percentage of CHF patients referred to AFCA, achieving effective rhythm control may also be 13 
useful to confirm the etiology of LV dysfunction and avoid unnecessary long-term treatments. 14 
 15 
AFCA in specific cardiomyopathies populations 16 
Eight observational studies reported the outcome of AFCA among HCM patients
44,45,46,47,48,49,50,51
. 17 
Consistently, all studies reported low efficacy after a single ablation procedure, especially during 18 
long-term follow-up. However, the efficacy raised up to 70-80% including the over 30% redo 19 
procedures; the prevalence of extensive left atrial ablation, including linear lesions or CFAEs, was 20 
higher compared to the general CHF population (Figure 1). This finding reflects a complex 21 
substrate typical of this specific cardiomyopathy
65
, characterized by severe left atrial enlargement. 22 
Being AF detrimental on both quality of life and prognosis of HCM patients
66
, its effective 23 
12 
 
treatment warrants careful attention, and AFCA may be considered precociously to achieve rhythm 1 
control. 2 
Although AF standard treatment in valvular cardiomyopathies is more commonly surgical
67
, 3 
performed concomitantly to heart surgery, 5 studies (four observational and one RCT) reported the 4 
outcome of AFCA among patients with significant valvular disease. Three of them
53,55,56
 included 5 
patients with prosthetic valves or previous percutaneous interventions for mitral rheumatic disease, 6 
reporting very low efficacy after a single procedure, raising up to 70% at a mean follow-up of 24 7 
months including over 50% repeated procedures. Gu et al.
55
 compared AFCA to surgical AF 8 
ablation, showing significantly better results for surgical ablation. This likely reflects the peculiar 9 
electroanatomical substrate of left atria determined by rheumatic heart disease
68
, characterized by 10 
profound structural remodeling requiring extreme substrate modification to achieve stable SR. The 11 
two studies including patients with moderate aortic or mitral defects
52,54
, instead, reported outcomes 12 
similar to the general population. This finding highlights the consequences on atrial substrate 13 
provided by a severe valvular disease or previous heart surgery compared to the minor atrial 14 
involvement present in lower degrees of valvular heart disease.  15 
 16 
Procedural protocol: PV isolation alone or extensive atrial ablation? 17 
The basis for extensive left atrial ablation lies in the pathophysiology of AF itself
69
: AF 18 
perpetuating in a left atrium with significant substrate modifications and advanced structural and 19 
electrical remodeling has historically been targeted by linear lesions
58,70
. However, linear lesions 20 
and CFAE ablation may increase the risk of iatrogenic atypical atrial re-entries (flutter) or atrial 21 
tachycardias if not transmural, incomplete, or not perfectly anchored to electrically inert 22 
structures
71
, counterbalancing the benefit derived by extensive atrial substrate modification
72
.  23 
13 
 
As illustrated in Figure 1, among the studies including unselected CHF patients, 55% of the patients 1 
underwent PV isolation alone, with a large heterogeneity among the studies (range 6-89%), 2 
resulting in SR maintenance comparable to the general non-CHF population. None of the 3 
observational studies was designed to compare the efficacy of different AFCA approaches. 4 
However, in the meta-analysis by Anselmino et al.
41
, including the largest available population, 5 
there was no difference in AFCA outcome performing PV isolation alone compared to additional 6 
linear ablation.  7 
Concerning specific cardiomyopathies, HCM and valvular cardiomyopathies have been approached 8 
by a much higher prevalence of left atrial linear lesions or CFAE, with only 37% of patients 9 
undergoing PV isolation alone. Even higher was the prevalence of linear lesions or CFAE among 10 
patients with severe or surgically corrected valvular disease, while patients with moderate valvular 11 
disease underwent more often PV isolation alone. This confirms once again the need of more 12 
aggressive substrate modification in cardiomyopathies with advanced left atrial substrate 13 
involvement. In patients with severe valvular cardiomyopathies, the ablation approach is in fact 14 
commonly surgical, and AFCA may play a role, perhaps as a hybrid approach, by completing the 15 
lesion set
73
. 16 
Despite this finding, however, extensive left atrial ablation strives to prove a net clinical benefit 17 
over PV isolation alone. CFAE ablation, for example, reported, after the introduction, minimally 18 
reproducible results and lower efficacy compared to traditional ablation protocols
74
. To date, rotors 19 
(areas of micro re-entries) and focal sources of high frequency activity have been proposed as new 20 
theoretically crucial targets for AF perpetuation
75
. However, although in non-CHF patients, the 21 
recent RADAR-AF trial
76
, randomizing patients with both paroxysmal and persistent AF to PV 22 
isolation alone versus respectively rotor ablation alone and PV isolation with rotor ablation, showed 23 
no benefit, but longer procedural times and higher risk of complications, as potentially silent 24 
14 
 
cerebral ischemias
77
, from assessing these targets. In accordance with these data, the Substrate and 1 
Trigger Ablation for Reduction of Atrial Fibrillation Part 2 (STAR AF 2) trial
78
, comparing PV 2 
isolation alone to strategies adding non-pulmonary vein targets in patients with persistent AF, did 3 
not show significant differences in AF recurrence between these alternative approaches. 4 
 5 
Clinical implications 6 
First, AFCA is a safe procedure, and can be performed with low complications rate in patients with 7 
complex atrial substrate, comorbidities and frailty
62
 such those with CHF. All the studies and meta-8 
analyses are concordant with the data concerning general non-CHF population. In fact, 9 
technological innovations contribute to rise AFCA safety: new superirrigated catheters lead to a 10 
significant reduction of fluid administration during the procedure
79
, particularly relevant among 11 
CHF patients. Moreover, magnetic resonance imaging plays an important role in correctly defining 12 
patients’ anatomy80, to avoid risks of access site related complications and to correctly map and 13 
target sites implicated in AF initiation and perpetuation
81
. However, due to the complexity of such 14 
patients, the suggestion is to refer to experienced, high volume Centers, also skilled to manage 15 
plausible complications. 16 
Second, AFCA improves LV function over short and long term follow-up, especially compared to 17 
medical treatment. This finding is not surprising: interruption of the vicious circle between AF and 18 
CHF, restoration of regular cardiac cycles and normal atrial mechanical function are likely to slow 19 
or even interrupt the negative electrical and structural remodeling of the failing heart. 20 
Third, AFCA relates to a significant improvement in quality of life, functional class and exercise 21 
tolerance, possibly related to the improvement of LV function and hemodynamic status of the 22 
patients. In general, shorter history of CHF and AF are both associated with improved outcome: 23 
15 
 
AFCA should be considered precociously to avoid progression of atrial substrate alteration. LA 1 
dimension is a marker of advanced substrate alteration, in fact patients with severe LA dilation 2 
present lower rate of SR maintenance. The absence of signs of advanced myocardial disease, such 3 
as late gadolinium enhancement at magnetic resonance or ischemic heart disease, are likely related 4 
to a significant improvement in LV function following SR restoration. Age, described as a predictor 5 
of outcome among the general population, despite not emerging independently related to AFCA 6 
outcome, resulted lower within the CHF patients included in the aforementioned studies compared 7 
to that of the general AFCA population. Finally, the role for new markers, as an advanced interatrial 8 
block or P wave duration
82
 among patients with CHF and relevant cardiomyopathies warrant further 9 
investigation. Given this, patients with a low likelihood to benefit from AFCA, benefit from 10 
antiarrhythmic treatment by amiodarone. Careful monitoring of side effects (thyroid dysfunction, 11 
hepatic and corneal disorders or pneumonitis), is warranted, but their impact is reasonably limited. 12 
In fact, patients with advanced CHF, unstable hemodynamic parameters and poor functional class 13 
are less likely to take advantage from this procedure, in front of high procedural risks; in this setting 14 
AFCA should not be proposed to improve symptoms or prognosis. 15 
Concerning the ideal AFCA protocol in this subset of patients, PV isolation alone seems to be 16 
sufficient in the majority of patients, at least for the first procedure, considering the potential 17 
arrhythmogenic “side effects” of extensive atrial ablation, reserving non-PV targets to repeated 18 
procedures for arrhythmic recurrences. To reduce the amount of redo procedures ablation tools 19 
innovation is needed to achieve safe, reproducible, and transmural PV isolation already after the 20 
first procedure. Only in the setting of specific, high risk subset populations such as HCM and severe 21 
valvular cardiomyopathies extensive left atrial ablation should be considered at first line to maintain 22 
SR. In facts, studies supporting PV isolation alone, such as STAR AF 2, include a very low 23 
16 
 
prevalence of patients with CHF, valvular cardiomyopathies or HCM, therefore, their results can 1 
not be translated to the present subset population without further investigation. 2 
Taking in mind these considerations, the flow chart proposed by our group to guide the decision 3 
making process in patients with CHF and concomitant AF is summarized in Figure 2. 4 
 5 
Future perspectives 6 
AFCA is gaining a significant role in CHF treatment of patients with concomitant AF, as confirmed 7 
by the latest guidelines
14
. However, the following points remain of concern. 8 
First of all, ablation protocol. PV isolation alone and/or additional non-PV targets, as in the general 9 
population, need to be tested in prospective randomized trials on CHF patients. 10 
Second, AFCA safety greatly improved over the past years. Due to the widespread expansion of 11 
AFCA and increasing referral to the procedures, efforts should be made to further lower 12 
complications rate. For example, performing the procedure on anticoagulants has proved to 13 
minimize the risk of clinical and asymptomatic thromboembolic complications in the general 14 
population, and this should be tested in the CHF subset. In addition, radiation exposure reduction, 15 
favored by the new fluoroscopy-zero technologies
83
, is warranted also in case of extensive ablation 16 
lesion sets.  17 
Finally, few randomized controlled trials specifically investigating the role of AFCA in the setting 18 
of CHF are currently ongoing (e.g. Catheter Ablation versus Standard conventional treatment in 19 
patients with LV dysfunction and Atrial Fibrillation [CASTLE-AF]
84
, AF Management In 20 
Congestive heart failure with Ablation [AMICA], Ablation vs. Amiodarone for Treatment of Atrial 21 
Fibrillation in Patients with Congestive Heart Failure and an Implanted ICD/CRTD [AATAC-AF]). 22 
17 
 
In addition to assessing the impact of AFCA on symptoms, LV function and functional class, 1 
further studies are encouraged to define optimal timing of AFCA during the natural CHF course, 2 
and most of all, the impact of AFCA on hard outcomes, such as mortality and stroke incidence.3 
18 
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Table 1. Observational studies and randomized controlled trials focusing on AFCA in CHF patients. Unweighted means are indicated as rough 1 
summary of each section. 2 
Author, 
Year (Ref) 
N. 
pts 
Age, 
years 
Paroxys
mal AF 
(%) 
NYHA 
class 
ICD/  
CRT  
(%) 
Pts on 
AADs 
(%) 
Summary of findings 
F-U, 
months 
F-U 
after 
last, 
months 
Success 
single 
(%) 
Redo 
(%) 
Success 
final 
(%) 
LVEF 
(%) 
Other 
parameters 
Observational studies 
Chen 2004 
(18) 
94 57 51 2.8 32 - 14 - 52 22 73 3641 ↑QoL 
Hsu 2004 
(19) 
58 56 9 2.3 - 78 - 12 28 50 78 3556 ↑LVD, 
QoL, 
exercise 
capacity 
and NYHA 
Tondo 
2006 (20) 
40 57 25 2.8 - 100 14 - 55 33 87 3347 ↑exercise 
capacity 
and  QoL 
Gentlesk 
2007 (21) 
67 54 70 - - - 6 - 55 31 86 4256 - 
Efremidis 
2007 (22) 
13 54 0 - - - 9 - 62 - 62 3652 - 
Nademanee 
2008 (23) 
129 67 40 - - - - 27 - 21 79 3037 - 
31 
 
Lutomsky 
2008 (24) 
18 - 100 - - 61 6 - 50 - - 4152 - 
De Potter 
2010 (25) 
36 52 39 - - 55 16 - 50 31 69 4158 - 
Choi 2010 
(26) 
15 56 67 1.7 7 73 16 - 47 27 73 3750 - 
Cha 2011 
(27) 
111 55 28 - - 67 12 - - - 76 3556 ↑QoL 
Anselmino 
2013 (28) 
196 60 22 2.1 - 50 46 27 45 30 62 4050 ↑NYHA 
and mitral 
regurgitatio
n 
Calvo 2013 
(29) 
36 52 24 - - - 6  70 31 83 4148 - 
Nedios 
2014 (30) 
69 61 33 2.4 26 4 28 - 40 46 65 3348 - 
Kosiuk 
2014 (31) 
73 59 32 - 100 25 12 - 37 30 - 3741 ↓ ICD 
shocks 
Lobo 2014 
(32) 
31 60 7 2.2 - - 20 - - 26 77 4459 - 
Bunch 
2015 (33) 
267 66 - - - - 60 - 39 - - 2742 ↓ death and 
CHF 
hospitalizati
on vs. AF, 
32 
 
no ablation 
Overall 1253 58  19  2.3 41  57  32  - 48  32  75  +13% - 
Randomized controlled trials 
Khan 2008 
(35) 
41 60 49 - - 100 6 - 71 20 88 2735 ↑QoL and 
6MWT 
distance vs. 
AV node 
ablation 
MacDonald 
2010 (36) 
22 62 0 2.9 - 0 10 - - 30 50 3641 QoL and 
6MWT: no 
difference 
vs. medical 
treatment 
Jones 2013 
(37) 
26 64 0 2.4 15 12 10 - 69 19 88 2132 ↑QoL and 
peak VO2, ↓  
BNP vs. 
rate control  
Hunter 
2014 (38) 
26 55 0 2.7 - - 6 - 38 54 81 3240 ↑QoL, 
NYHA 
class peak 
VO2, ↓  
BNP vs. 
rate control 
Overall 115 60  12  2.7  - - 8  - 59  31  77  +8% - 
AFCA in patients with tachycardiomyopathy 
Calvo 2013 
(29) 
61 
52 
22 - - - 
6 
- 
73 - 80 
4054 
TCM 
doesn’t 
relate to AF 
recurrence 
33 
 
Sairaku 
2014 (43) 
52 61 0 - - - 18 - - - 67 3554 ↑ LVEF 
improveme
nt in 
patients in 
SR; TCM 
doesn’t 
relate to AF 
recurrence 
Overall 113 56  11  - - - 12  - 73 - 74 +16% - 
AFCA in patients with CHF with preserved LV ejection fraction 
Machino-
Ohtsuka 
2013 (34) 
74 65 31 2.2 - 15 34 - 27 68 73 - LV strain 
and 
diastolic 
function 
improve in 
patients in 
SR 
 1 
AFCA: catheter ablation of atrial fibrillation. CHF: chronic heart failure. AF: atrial fibrillation. FU: follow-up. LVEF: left ventricular ejection 2 
fraction. QoL: quality of life. LVD: left ventricular diameter. ICD: implantable cardioverter defibrillator. 6MWT: 6-minute walking test. TCM: 3 
tachycardiomyopathy. SR: sinus rhythm.  4 
34 
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35 
 
 1 
Table 2. Observational studies concerning AFCA in specific subset cardiomyopathies. Unweighted means are reported as rough summary of each 2 
section. 3 
Hypertrophic cardiomyopathy 
Author, year 
(valvular 
cardiomyopathy 
subtype) 
N. 
patients 
Age, 
years 
Paroxysmal 
AF (%) 
NYHA 
class 
ICD/ CRT 
(%) 
Follow-
up 
(month
s) 
Follow-up 
after last 
(months) 
Success 
single 
(%) 
Success 
final 
(%) 
Procedural 
characteristi
cs 
Complicatio
ns (%) 
Liu, 2005 (44) 4 57 100 2.0 50 6 - 75 100 PVI 0 
Kilicaslan, 2006 
(45) 
27 55 52 - - 12 9 52 70 PVI 0 
Bunch, 2008 (46) 33 51 64 - - 30 - - 74 24% PVI; 
76% PVI + 
7 scheme 
12 
Di Donna, 2010 
(47) 
61 54 57 2.0 28 40 29 28 67 PVI + 7 
scheme 
0 
Derejko, 2013 (48) 30 49 47 1.8 53 22 12 33 53 42% PVI, 
58% PVI + 
7 scheme + 
CFAE 
0 
Santangeli, 2013 43 59 28 1.9 63 15 - 49 94 PVI + 7 
scheme + 
0 
36 
 
(49) CFAE 
Mussigbrodt, 2014 
(50) 
22 57 45 - 36 - - 41 54 68% PVI, 
32% PVI + 
7 scheme 
5 
Okamatsu, 2014 
(51) 
22 65 23 - - 21 21 45 59 PVI - 
Overall 242 56  52  1.9  46 18  - 46  71  - 2. 
Valvular cardiomyopathies 
Khaykin, 2004 
(52) (moderate  
mitral or aortic 
stenosis or 
regurgitation) 
102 64 37 1.4 - 11 - 83 93 PVI 3 
Wang, 2009 (53) 
(Mitral or aortic 
prosthetic valves 
or previous mitral 
commissurotomy) 
51 48 0 - - 12 - 51 67 PVI + 
CFAE 
2 
Miyazaki, 2010 
(54) (moderate  
mitral or aortic 
stenosis or 
regurgitation) 
45 66 80 1.3 - 26 24 47 78 80% PVI, 
20% PVI + 
7 scheme 
4.3 
37 
 
Gu, 2010 (55) 
(Rheumatic heart 
disease 6 months 
after valvular 
surgery) 
47 55 0 - - 54 - 32 79 57% PVI + 
CFAE + 7 
scheme; 
33% PVI + 
CFAE; 10% 
PVI alone 
4 
Derejko, 2014 (56) 
(Previous mitral 
valve surgery or 
percutaneous 
mitral 
commissurotomy) 
14 55 29 - - 23 - 36 71 93% PVI + 
CFAE + 7 
scheme; 7% 
PVI alone 
0 
Overall 259 58  29 - - 25 - 49 77  - 2.2 
 1 
AFCA: atrial fibrillation catheter ablation. PVI: pulmonary vein isolation. CFAE: complex fractioned atrial electrograms. 2 
 3 
 4 
 5 
6 
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Table 3. Meta-analyses of published studies on AFCA in CHF patients.  1 
 N. studies N. 
patients 
Success 
single 
(%) 
Success 
final (%) 
Complications 
(%) 
LVEF 
improvement  
Other findings 
Wilton, 2010 (38) 8 483 45-73 69-96 4.8 +11% - 
Dagres, 2011 (39) 9 354 - - 6.7 +11% CAD relates to no LVEF 
improvement 
Anselmino, 2014 
(40) 
26 1,838 36-44 54-67 4.2 +13% ↓NT-proBNP and patients 
with LVEF<35%; time to 
first AF and CHF diagnosis 
relate to recurrences 
Ganesan, 2014 
(41) 
19 914 56 82 5.5 +13% Improvement in exercise 
capacity and QoL 
 2 
AFCA: atrial fibrillation catheter ablation. CHF: chronic heart failure. LVEF: left ventricular ejection fraction. CAD: coronary artery disease. QoL: 3 
quality of life.4 
39 
 
Figure legends 1 
Figure 1. AFCA protocol according to underlying cardiomyopathies.  2 
AFCA: atrial fibrillation catheter ablation. CHF: chronic heart failure. HCMP: hypertrophic 3 
cardiomyopathy. CFAE: complex fractioned atrial electrograms. 4 
 5 
Figure 2. Proposed flow-chart for AF management in patients with concomitant CHF.  6 
¶ Heart failure defined as the presence of structural cardiomyopathy with left ventricular 7 
ejection fraction <50% and symptoms of heart failure (NYHA class > I) 8 
* Dotted line refers to severe valvular cardiomyopathy and hypertrophic cardiomyopathy 9 
# Long-standing persistent AF should be approached as persistent AF, except in case of severe 10 
left atrial dilation (volume > 150 ml) 11 
‡ Dronedarone may be considered in the absence of valuable alternatives in stable (NYHA class 12 
I-II) CHF patients 13 
§ Catheter ablation as first line therapy for patients with paroxysmal AF and favorable baseline 14 
characteristics (left atrial dimension, short AF and CHF history) and for those intolerant to or 15 
rejecting antiarrhythmic drug therapy 16 
¤ As recommended in specific guidelines 17 
AF: atrial fibrillation. CHF: chronic heart failure. ICD: implantable cardioverter defibrillator. 18 
CRT: cardiac resynchronization therapy. 19 
